Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2018’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)

– The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects

– The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Idera Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Overview

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Companies Involved in Therapeutics Development

Astellas Pharma Inc

Idera Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Drug Profiles

Antisense Oligonucleotide to Inhibit NLRP3 for Interstitial Cystitis and Uveitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6294 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl sulfoxide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-16357 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-08 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mesalamine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URG-801 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Dormant Projects

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Discontinued Products

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Product Development Milestones

Featured News & Press Releases

Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by Astellas Pharma Inc, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by Idera Pharmaceuticals Inc, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by Kytogenics Pharmaceuticals Inc, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by Lipella Pharmaceuticals Inc, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by UCB SA, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by Urigen Pharmaceuticals Inc, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Pipeline by Xigen SA, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Dormant Projects, H2 2018

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports